R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse
Status:
Not yet recruiting
Trial end date:
2028-01-30
Target enrollment:
Participant gender:
Summary
This is a double-center, single-arm, phase 2 study to evaluate the efficacy and safety of
R-CDOP regimen combined with intrathecal methotrexate in chemo-naive diffuse large B-cell
lymphoma patients with high-risk of CNS relapse.